

**web:** <http://covidcirrhosis.org>  
**email:** [covid.cirrhosis@unc.edu](mailto:covid.cirrhosis@unc.edu)  
**twitter:** @SecureCirrhosis


**web:** <https://covid-hep.net>  
**email:** [info@covid-hep.net](mailto:info@covid-hep.net)  
**twitter:** @COVIDHep

## Combined weekly update – 05 May 2020

We continue to wish everyone working to fight COVID-19 well and we welcome you to this combined update from our two collaborating international registries: **SECURE-Cirrhosis** covering North and South America, China/Japan/Korea and **COVID-Hep with EASL** covering the rest of the world in an attempt to collate clinical details of patients with chronic liver disease who develop COVID-19.

### Total cohort (n = 419)


#### Submissions over time



#### Characteristics

386 (93%) hospitalised  
269 (64.2%) men  
Median age 59 years (IQR 47-68)

#### Submissions from 25 countries



### Chronic liver disease, non-cirrhotic (n = 176)

#### Major outcomes

Intensive care admission	32	18%
Invasive ventilation	30	17%
Death	10	6%

### Cirrhosis (n = 185)

#### Major aetiologies

Alcohol	55	30%
Non-alcoholic steatohepatitis	32	17%
Hepatitis C	20	11%
Hepatitis B	17	9%
Haemochromatosis	15	8%
Autoimmune hepatitis	9	5%
Alcohol & HCV	9	5%
Others and mixed	28	15%

#### Decompensation

Any	71	38%
New or worse ascites	42	23%
New or worse encephalopathy	40	22%
Variceal bleeding	5	3%

#### Major outcomes

Intensive care admission	45	24%
Invasive ventilation	28	15%
Death	68	37%

### Liver transplant (n = 58)

#### Major outcomes

Intensive care admission	13	22%
Invasive ventilation	12	21%
Death	13	22%